ArticleHealth science reports2026
Mpox in South Asia: A Narrative Review on Epidemiology, Preparedness, and Preventive Strategies.
Article in Health science reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Monkeypox (Mpox), due to its growing global concern, was declared a public health emergency of worldwide concern by the World Health Organization in August 2024. The monkeypox virus (MPXV), once limited to African regions, has now spread to South Asia, including Pakistan, India, Nepal, and Sri Lanka, and there have been over 109,699 cases and 234 deaths reported globally till now. This review aims to provide an overview of the spread of Mpox in South Asia, the preparedness of the South Asian countries, and the preventive and control measures. Methods: This narrative review was conducted through a comprehensive literature search of online databases including PubMed, Google Scholar, World Health Organization (WHO) resources, World Bank Open Data, and relevant public health reports from South Asian countries. Published literature was reviewed to extract information on mpox transmission, pathogenesis, epidemiology, preventive measures, healthcare preparedness, and regional impact. Results: Currently there is no clinical treatment for Mpox. Several antiviral agents are undergoing investigation, including cidofovir, brincidofovir, and so forth. In vitro potency of cidofovir for Mpox was found to be highest among other antivirals in a study. Tecovirimat did not significantly reduce the time required to heal Mpox lesions in two separate studies. In a different investigation involving trifluridine, tecovirimat, when used in combination, showed a substantially additive effect in dermal fibroblast cells (DF) and immortalized human conjunctival epithelial cells HConEpic. Alteration of biological traits, human behavior and clinical manifestations of Mpox mandates a need for surveillance of transmission. Regional outbreak patterns were identified through this study. Control measures include vaccination of susceptible individuals and avoiding contact with infected animals and humans. Conclusion: Mpox poses a growing public health threat in South Asia due to population density, limited healthcare infrastructure, and underreporting. Strengthening vaccination, antiviral management, and diagnostic capacity is crucial to control transmission. Tailored region-specific strategies, including surveillance and stigma reduction, are essential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.